

All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

WEDNESDAY 15th JUNE 2016 COMMENCING 09:30 AM

AT THE [PARK INN HOTEL CARDIFF NORTH](#), CIRCLE WAY EAST

LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

- | | Enclosure |
|--|----------------------------|
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0616 |
| 5. Chairman's report | |
| 6. Appraisal 1: Full Submission
Misoprostol (Mysodelle[®]) for induction of labour in women with an unfavourable cervix, from 36 weeks gestation, in whom induction is clinically indicated | 2/AWMSG/0616
Appendices |
| 7. Appraisal 2: Full Submission
Olanzapine (ZypAdhera[®]) for the maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine | 3/AWMSG/0616
Appendices |

To protect commercial confidentiality the following appraisal will be held in private

- | | |
|---|----------------------------|
| 8. Appraisal 3: Limited Submission (PAS)
Evolocumab (Repatha[®]) for the treatment in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies | 4/AWMSG/0616
Appendices |
|---|----------------------------|

Date of next meeting: 13th July 2016 in Cardiff